Efficiency of L-LYSINE AESCINATE
L-lysine aescinate – is the only parenteral angioprotector which indicated for treatment and prevention of edema of different localizations. However the most beneficial application of this drug is where medicine possibilities are limited – this is a treatment of intracranial hypertension in traumatic brain injury (TBI) and stroke.
L-lysine aescinate has expressed and quick anti-edematous effect, decreases/eliminates brain edema, reduces intracranial hypertension and brain structures dislocation. L-lysine aescinate increases vein’s tonicity improving blood outflow from a skull. An important issue is its ability to normalize rheology and improve microcirculation. Lysosomal enzymes inhibition by L-lysine aescinate leads to reducing of vessel permeability and vessel-tissue barrier restoration. The drug has a moderate anti-inflammatory and analgesic activities what makes it a required component in the therapy of the patients with TBI and stroke.
Efficacy and safety of L-lysine aescinate are studied in 12 trials with 1727 patients (727 are treated by L-lysine aescinate added to standard therapy). The next end points were studied: ICP changes, NIHSS scale dynamics, Glasgow outcome scale score (GOS), Glasgow coma scale score (GCS), mortality. Average treatment duration was 7-10 days (from 6 to 12), 10-20 mg/d.
Metaanalysis has demonstrated the next results:
- L-lysine aescinate reduced ICP by 21,87% vs 6,63% in standard therapy group;
- L-lysine aescinate caused more positive dynamics in GSC score -66,89% score reduction vs 40,61%;
- Glasgow Outcome Scale score shown that patients which received L-lysine aescinate had reached better results by 20,14% vs 13,79% in patients on standard therapy;
- NIHSS scores were different significantly in groups in favor of L-lysine aescinate group on the 30th day or on discharge, р >0,001;
- L-lysine aescinate administration added to the standard therapy significantly reduced the likelihood of death (CE=0,45, 95% CI 0,31-0,65) and enhanced a chance to survive (CE=2,22, 95% CI 1,54-3,21);
- Adverse effects rate in the trials responses to a low level by WHO classification*.
*Dzyak L., Sirko A. Меta-analysis of efficacy and tolerability of L-lysine aescinate in the treatment of TBI and acute brain circulation disorders. News of medicine and pharmacy, №6 (76), 2015
В даному розділі сайту міститься повна інформація про препарат, застосування та ефективність L-ЛІЗИНУ ЕСЦИНАТ від виробника. Будь-яку додаткову інформацію про препарат ви завжди можете дізнатися надіславши запит формою зворотного зв'язку на офіційному сайті виробника. Розчин L-ЛІЗИНУ ЕСЦИНАТ для ін'єкцій – строго рецептурний препарат, застосування якого допускається тільки фахівцями в галузі медицини, випускається в упаковках по 10 ампул, по 5 мл у кожній ампулі. Ефективність L-ЛІЗИНУ ЕСЦИНАТ підтверджена численними дослідженнями та різнобічним досвідом застосування, з якими ви можете ознайомитись у розділах «публікації та матеріали», «відеолекції».